MedPath

NATIONAL INSTITUTES OF HEALTH

NATIONAL INSTITUTES OF HEALTH logo
🇺🇸United States
Ownership
Subsidiary, Private
Established
1948-01-01
Employees
1K
Market Cap
-
Website
http://www.nidcr.nih.gov

Randomized Trial of EUS Neurolysis in Pancreas Cancer

Phase 3
Completed
Conditions
Pancreatic Neoplasms
First Posted Date
2006-01-19
Last Posted Date
2015-10-14
Lead Sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Target Recruit Count
26
Registration Number
NCT00279292
Locations
🇺🇸

Mayo Clinic Scottsdale, Scottsdale, Arizona, United States

🇺🇸

Mayo Clinic Jacksonville, Jacksonville, Florida, United States

TEDDY - The Environmental Determinants of Diabetes in the Young

Active, not recruiting
Conditions
Type 1 Diabetes Mellitus
First Posted Date
2006-01-19
Last Posted Date
2024-11-25
Lead Sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Target Recruit Count
8667
Registration Number
NCT00279318
Locations
🇫🇮

Wellbeing Services County of Southwest Finland, Turku, Finland

🇺🇸

University of Colorado Health Sciences Center, Denver, Colorado, United States

🇺🇸

Augusta University, Augusta, Georgia, United States

and more 3 locations

Cediranib Maleate in Treating Patients With Persistent, Recurrent, or Refractory Advanced Ovarian Epithelial, Peritoneal Cavity, or Fallopian Tube Cancer

Phase 2
Completed
Conditions
Recurrent Fallopian Tube Cancer
Recurrent Ovarian Epithelial Cancer
Recurrent Primary Peritoneal Cavity Cancer
Interventions
Other: laboratory biomarker analysis
First Posted Date
2006-01-18
Last Posted Date
2018-08-29
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
74
Registration Number
NCT00278343
Locations
🇺🇸

City of Hope Medical Group Inc, Pasadena, California, United States

🇺🇸

City of Hope, Duarte, California, United States

🇺🇸

Ingalls Memorial Hospital, Harvey, Illinois, United States

and more 25 locations

Vorinostat in Treating Patients With Kidney Cancer

Phase 2
Completed
Conditions
Recurrent Renal Cell Carcinoma
Stage IV Renal Cell Cancer
Interventions
First Posted Date
2006-01-18
Last Posted Date
2017-11-14
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
14
Registration Number
NCT00278395
Locations
🇺🇸

Institute for Drug Development, San Antonio, Texas, United States

🇺🇸

Cancer Therapy and Research Center at The UT Health Science Center at San Antonio, San Antonio, Texas, United States

Radiation Therapy in Treating Patients With Cervical Cancer

Phase 2
Completed
Conditions
Cervical Cancer
First Posted Date
2006-01-18
Last Posted Date
2013-06-20
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
20
Registration Number
NCT00278304
Locations
🇺🇸

Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland, United States

Flavopiridol and Vorinostat in Treating Patients With Relapsed or Refractory Acute Leukemia or Chronic Myelogenous Leukemia or Refractory Anemia

Phase 1
Completed
Conditions
Blastic Phase Chronic Myelogenous Leukemia
Recurrent Adult Acute Lymphoblastic Leukemia
Recurrent Adult Acute Myeloid Leukemia
Refractory Anemia With Excess Blasts
Relapsing Chronic Myelogenous Leukemia
Untreated Adult Acute Lymphoblastic Leukemia
Untreated Adult Acute Myeloid Leukemia
Interventions
First Posted Date
2006-01-18
Last Posted Date
2013-04-02
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
24
Registration Number
NCT00278330
Locations
🇺🇸

Virginia Commonwealth University, Richmond, Virginia, United States

Sorafenib in Treating Patients With Recurrent Non-Hodgkin's Lymphoma

Phase 2
Completed
Conditions
Anaplastic Large Cell Lymphoma
Recurrent Mantle Cell Lymphoma
Recurrent Adult Diffuse Large Cell Lymphoma
Interventions
Other: laboratory biomarker analysis
First Posted Date
2006-01-18
Last Posted Date
2013-02-07
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
33
Registration Number
NCT00278382
Locations
🇺🇸

University of Maryland Greenebaum Cancer Center, Baltimore, Maryland, United States

Temsirolimus in Treating Patients With Metastatic Solid Tumor or Lymphoma That Cannot Be Removed By Surgery Who Have Different Levels of Liver Function

Phase 1
Completed
Conditions
Hepatic Complications
Lymphoma
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
Other: laboratory biomarker analysis
Other: pharmacological study
First Posted Date
2006-01-11
Last Posted Date
2013-01-30
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
130
Registration Number
NCT00275093
Locations
🇺🇸

Cancer Therapy and Research Center at The UT Health Science Center at San Antonio, San Antonio, Texas, United States

Insulin Resistance in Severely Obese Patients

Completed
Conditions
Obesity
Insulin Resistance
Diabetes
First Posted Date
2006-01-11
Last Posted Date
2010-03-18
Lead Sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Target Recruit Count
48
Registration Number
NCT00275223
Locations
🇺🇸

Emory University Hospital, Atlanta, Georgia, United States

Glomerular Injury of Preeclampsia

Not Applicable
Completed
Conditions
Pre-Eclampsia
First Posted Date
2006-01-11
Last Posted Date
2010-01-14
Lead Sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Target Recruit Count
45
Registration Number
NCT00275158
Locations
🇺🇸

Stanford University Medical Center, Stanford, California, United States

© Copyright 2025. All Rights Reserved by MedPath